A panelist discusses how guidelines from organizations like the National Comprehensive Cancer Network (NCCN) can improve clinician awareness and adoption of molecular testing in community oncology settings while acknowledging that some effective treatments work across patient populations without requiring biomarker stratification.
Video content above is prompted by the following:
Improving Clinician Awareness and Adoption in Community Settings
Strategies to improve molecular testing adoption in community oncology include the following:
Recent examples of non–biomarker-directed advances include relacorilant (cortisol blocker) with nab-paclitaxel showing improved progression-free survival and overall survival in platinum-resistant ovarian cancer, and tisotumab vedotin (targeting tissue factor) in cervical cancer.
Collaboration between academic and community settings, participation in clinical research, and tissue collection for biomarker discovery remain essential for continued progress in treatment personalization.
Immune Checkpoint Inhibitors More Effective vs Bevacizumab in Nonsquamous NSCLC
August 6th 2025Bevacizumab combined with chemotherapy was not as effective in advanced driver gene-negative nonsquamous non–small cell lung cancer (NSCLC) compared with immune checkpoint inhibitors plus chemotherapy.
Read More
Higher Oxidative Balance Score Linked to Lower Systemic Inflammation, Study Finds
August 5th 2025Researchers discovered a significant negative correlation between an individual's oxidative balance score and systemic immune-inflammation index, highlighting the role of antioxidants in reducing inflammation.
Read More
Bridging the Gaps: New Strategies for Preventing Cardiovascular Disease
July 31st 2025During the Addressing Cardiovascular Risk and Intervening Early webinar, experts discussed innovative strategies for cardiovascular disease prevention, emphasizing risk assessment, lifestyle changes, and collaborative care to improve patient outcomes.
Read More